MX2007008722A - Elementos de aglutinacion especifica para el factor de crecimiento nervioso. - Google Patents

Elementos de aglutinacion especifica para el factor de crecimiento nervioso.

Info

Publication number
MX2007008722A
MX2007008722A MX2007008722A MX2007008722A MX2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A MX 2007008722 A MX2007008722 A MX 2007008722A
Authority
MX
Mexico
Prior art keywords
ngf
antibody molecules
specific binding
binding members
psoriasis
Prior art date
Application number
MX2007008722A
Other languages
English (en)
Spanish (es)
Inventor
Ruth Franks
Andrew Grier Buchanan
Albert George Thom
Fraser Ewing Welsh
Philip Antony Bland-Ward
Matthew Alexander Sleeman
Carl Anthony Matthews
Celia Patricia Hart
Jon Hawkinson
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Publication of MX2007008722A publication Critical patent/MX2007008722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
MX2007008722A 2005-01-24 2006-01-24 Elementos de aglutinacion especifica para el factor de crecimiento nervioso. MX2007008722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64558705P 2005-01-24 2005-01-24
PCT/GB2006/000238 WO2006077441A1 (en) 2005-01-24 2006-01-24 Specific binding members for ngf

Publications (1)

Publication Number Publication Date
MX2007008722A true MX2007008722A (es) 2008-02-15

Family

ID=36088563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008722A MX2007008722A (es) 2005-01-24 2006-01-24 Elementos de aglutinacion especifica para el factor de crecimiento nervioso.

Country Status (17)

Country Link
US (2) US9315571B2 (https=)
EP (2) EP1846451B1 (https=)
JP (1) JP5096167B2 (https=)
KR (1) KR101298383B1 (https=)
CN (1) CN101107268B (https=)
AU (1) AU2006207338B2 (https=)
BR (1) BRPI0606933B8 (https=)
CA (1) CA2595800C (https=)
ES (1) ES2435691T3 (https=)
IL (1) IL183752A (https=)
MX (1) MX2007008722A (https=)
NO (1) NO343064B1 (https=)
NZ (1) NZ556157A (https=)
PT (1) PT1846451E (https=)
RU (1) RU2406728C2 (https=)
WO (1) WO2006077441A1 (https=)
ZA (1) ZA200705754B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7488630B2 (en) 2007-03-06 2009-02-10 International Business Machines Corporation Method for preparing 2-dimensional semiconductor devices for integration in a third dimension
BRPI0815370B8 (pt) * 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
MX2010006610A (es) * 2007-12-20 2010-09-30 Cytos Biotechnology Ag Conjugados de factor de crecimiento de nervios y usos de los mismos.
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
EP2431463A4 (en) * 2009-05-13 2012-12-26 Shionogi & Co TESTS FOR VISCERAL ADIPOSITAS AND ITS USE
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6190723B2 (ja) * 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
PT2743348T (pt) 2011-08-11 2018-02-23 Astellas Pharma Inc Novo anticorpo anti-ngf humano
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
RU2678810C2 (ru) 2014-02-02 2019-02-01 Медиммун Лимитед ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα
CA2986210C (en) 2015-05-22 2022-04-26 Astellas Pharma Inc. Novel anti-human ngf antibody fab fragment
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
JP2021517461A (ja) 2018-03-12 2021-07-26 ゾエティス・サービシーズ・エルエルシー 抗ｎｇｆ抗体およびその方法
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
BR112023004840A2 (pt) 2020-09-28 2023-04-18 Medimmune Ltd Compostos e métodos para tratamento de dor
CN121410259B (zh) * 2025-12-30 2026-03-20 北京索莱宝科技有限公司 用于检测人β-NGF含量的双抗夹心ELISA试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503722A (ja) * 1990-11-30 1994-04-28 アボット・ラボラトリーズ 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
EP1242458A2 (en) * 1999-12-13 2002-09-25 Cambridge Antibody Technology Limited Brain specific binding members
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2003240822A1 (en) 2002-05-30 2003-12-19 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
EP1545615A4 (en) 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CN101014364B (zh) * 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体

Also Published As

Publication number Publication date
RU2406728C2 (ru) 2010-12-20
EP2298345A3 (en) 2012-03-21
EP1846451A1 (en) 2007-10-24
JP5096167B2 (ja) 2012-12-12
AU2006207338B2 (en) 2011-12-08
AU2006207338A1 (en) 2006-07-27
BRPI0606933A2 (pt) 2009-12-01
KR101298383B1 (ko) 2013-08-20
HK1105208A1 (en) 2008-02-06
CA2595800A1 (en) 2006-07-27
US9701746B2 (en) 2017-07-11
WO2006077441A1 (en) 2006-07-27
NO343064B1 (no) 2018-10-22
PT1846451E (pt) 2013-08-28
CN101107268A (zh) 2008-01-16
KR20070100330A (ko) 2007-10-10
US20160297878A1 (en) 2016-10-13
NZ556157A (en) 2009-09-25
EP2298345A2 (en) 2011-03-23
IL183752A (en) 2013-12-31
BRPI0606933B1 (pt) 2019-12-10
US9315571B2 (en) 2016-04-19
WO2006077441A8 (en) 2008-04-10
ES2435691T3 (es) 2013-12-23
ZA200705754B (en) 2008-06-25
US20080107658A1 (en) 2008-05-08
CN101107268B (zh) 2012-06-27
NO20074266L (no) 2007-10-23
CA2595800C (en) 2014-07-08
IL183752A0 (en) 2007-09-20
BRPI0606933B8 (pt) 2021-05-25
JP2008527989A (ja) 2008-07-31
EP1846451B1 (en) 2013-05-15
RU2007132020A (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
MX2007008722A (es) Elementos de aglutinacion especifica para el factor de crecimiento nervioso.
Sperry Psychological treatment of chronic illness: The biopsychosocial therapy approach.
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2005051366A3 (en) Diaryl urea derivatives in the treatment of protein kinase dependent diseases
WO2008065378A3 (en) Binding members for interleukin-6
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
Courneya The emerging role of exercise as a cancer treatment
Laurencin et al. Fracture repair: challenges and opportunities
Schumann et al. Advanced exercise prescription for cancer patients and its application in Germany
WO2006131651A3 (fr) Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée
Yang et al. Trends in acupuncture therapy in cardiovascular disease: a bibliometric analysis.
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
Souza et al. RESPIRATORY MUSCLE TRAINING IN PEOPLE WITH COPD: A SYSTEMATIZED REVIEW
ATE470706T1 (de) Regulation einer kinase, 'reguliert in copd kinase' (rc-kinase)
Mukhopadhyay et al. The Role of Iron Chelation Activity of Wheat Grass Juice in Blood Transfusion Requirement of Intermediate Thalassaemia.
Ferro et al. INFLUENCE OF PHOTOBIOMODULATION ON CELL VIABILITY OF MULTIPOTENT MESENCHYMAL STEM CELLS FROM ADIPOSE TISSUE IN VITRO
McClung Example
Alape et al. Expiratory Central Airway Collapse and Medical Management: Outcome Analysis
Belch et al. Bortezomib [VELCADE™], Pegylated Liposomal Doxorubicin [DOXIL/CAELYX®] and Dexamethasone in the Treatment of Previously Untreated Multiple Myeloma Patients: Impact on Quality-of-Life.
Usmanova et al. Ekaterina Usmanova, Maria Iakovleva, Olga Shchelkova, & Maria Berezantseva. Quality of life and coping with disease-related stress in patients after amputation of a lower limb
Cornette et al. Prevalence and predictors of sleep disordered breathing in patients undergoing chronic ambulatory intermittent hemodialysis

Legal Events

Date Code Title Description
FG Grant or registration